Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma

Loredana Bianchi, Luigi Rossi, Federica Tomao, Anselmo Papa, Federica Zoratto, Silverio Tomao

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical outcomes and show different responses to therapy. Overall, the incidence of kidney cancer has increased worldwide in the last years. Although the most common type of kidney cancer is localized renal cell carcinoma (RCC), with a 5-year survival rate of 85%, about one third of patients present advanced or metastatic disease at diagnosis, with a 5-year survival rate of only 10%. Multi-targeted receptor tyrosine kinase inhibitors (TKIs, sunitinib and sorafenib), the anti-VEGF MAB bevacizumab in association with interferon-a, and the mTOR inhibitors are now approved for the treatment of mRCC. Recently, the novel agents pazopanib and axitinib have also demonstrated efficacy in mRCC patients. Several recent retrospective and prospective trials have suggested that some of their adverse events, such as hypertension, hypothyroidism, and hand foot syndrome (HFS) may act as potential biomarkers of response and efficacy of treatment. In this review, we analyzed the studies that have suggested a relationship between hypothyroidism onset and a better outcome of mRCC patients treated with TKIs. The biological mechanisms suggesting and explaining this correlation are not well known and different speculative theories have been considered in order to investigate the clinical link between hypothyroidism occurrence and the prolonged therapy with TKIs in solid tumors. Furthermore, the management of this unexplained side effect is very important to maximize the efficacy of therapy in mRCC patients because there is a clear and consistent relationship between drug dose and efficacy of treatment. Certainly, other studies are needed to clarify whether a better outcome is associated with hypothyroidism induced to TKIs in patients with mRCC.

Original languageEnglish
JournalEndocrine-Related Cancer
Volume20
Issue number5
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Renal Cell Carcinoma
Protein-Tyrosine Kinases
Kidney Neoplasms
Thyroid Gland
Hypothyroidism
Survival Rate
Hand-Foot Syndrome
Receptor Protein-Tyrosine Kinases
Therapeutics
Interferons
Vascular Endothelial Growth Factor A
Biomarkers
Hypertension
Incidence
Pharmaceutical Preparations
Neoplasms

Keywords

  • Carcinoma
  • Hypothyroidism
  • Metastatic renal cell
  • Tyrosine kinase inhibitors
  • VEGF

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Bianchi, L., Rossi, L., Tomao, F., Papa, A., Zoratto, F., & Tomao, S. (2013). Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocrine-Related Cancer, 20(5). https://doi.org/10.1530/ERC-13-0201

Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. / Bianchi, Loredana; Rossi, Luigi; Tomao, Federica; Papa, Anselmo; Zoratto, Federica; Tomao, Silverio.

In: Endocrine-Related Cancer, Vol. 20, No. 5, 10.2013.

Research output: Contribution to journalArticle

Bianchi, L, Rossi, L, Tomao, F, Papa, A, Zoratto, F & Tomao, S 2013, 'Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma', Endocrine-Related Cancer, vol. 20, no. 5. https://doi.org/10.1530/ERC-13-0201
Bianchi, Loredana ; Rossi, Luigi ; Tomao, Federica ; Papa, Anselmo ; Zoratto, Federica ; Tomao, Silverio. / Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. In: Endocrine-Related Cancer. 2013 ; Vol. 20, No. 5.
@article{e96aef6007254829a09619646ede400f,
title = "Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma",
abstract = "The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical outcomes and show different responses to therapy. Overall, the incidence of kidney cancer has increased worldwide in the last years. Although the most common type of kidney cancer is localized renal cell carcinoma (RCC), with a 5-year survival rate of 85{\%}, about one third of patients present advanced or metastatic disease at diagnosis, with a 5-year survival rate of only 10{\%}. Multi-targeted receptor tyrosine kinase inhibitors (TKIs, sunitinib and sorafenib), the anti-VEGF MAB bevacizumab in association with interferon-a, and the mTOR inhibitors are now approved for the treatment of mRCC. Recently, the novel agents pazopanib and axitinib have also demonstrated efficacy in mRCC patients. Several recent retrospective and prospective trials have suggested that some of their adverse events, such as hypertension, hypothyroidism, and hand foot syndrome (HFS) may act as potential biomarkers of response and efficacy of treatment. In this review, we analyzed the studies that have suggested a relationship between hypothyroidism onset and a better outcome of mRCC patients treated with TKIs. The biological mechanisms suggesting and explaining this correlation are not well known and different speculative theories have been considered in order to investigate the clinical link between hypothyroidism occurrence and the prolonged therapy with TKIs in solid tumors. Furthermore, the management of this unexplained side effect is very important to maximize the efficacy of therapy in mRCC patients because there is a clear and consistent relationship between drug dose and efficacy of treatment. Certainly, other studies are needed to clarify whether a better outcome is associated with hypothyroidism induced to TKIs in patients with mRCC.",
keywords = "Carcinoma, Hypothyroidism, Metastatic renal cell, Tyrosine kinase inhibitors, VEGF",
author = "Loredana Bianchi and Luigi Rossi and Federica Tomao and Anselmo Papa and Federica Zoratto and Silverio Tomao",
year = "2013",
month = "10",
doi = "10.1530/ERC-13-0201",
language = "English",
volume = "20",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "5",

}

TY - JOUR

T1 - Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma

AU - Bianchi, Loredana

AU - Rossi, Luigi

AU - Tomao, Federica

AU - Papa, Anselmo

AU - Zoratto, Federica

AU - Tomao, Silverio

PY - 2013/10

Y1 - 2013/10

N2 - The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical outcomes and show different responses to therapy. Overall, the incidence of kidney cancer has increased worldwide in the last years. Although the most common type of kidney cancer is localized renal cell carcinoma (RCC), with a 5-year survival rate of 85%, about one third of patients present advanced or metastatic disease at diagnosis, with a 5-year survival rate of only 10%. Multi-targeted receptor tyrosine kinase inhibitors (TKIs, sunitinib and sorafenib), the anti-VEGF MAB bevacizumab in association with interferon-a, and the mTOR inhibitors are now approved for the treatment of mRCC. Recently, the novel agents pazopanib and axitinib have also demonstrated efficacy in mRCC patients. Several recent retrospective and prospective trials have suggested that some of their adverse events, such as hypertension, hypothyroidism, and hand foot syndrome (HFS) may act as potential biomarkers of response and efficacy of treatment. In this review, we analyzed the studies that have suggested a relationship between hypothyroidism onset and a better outcome of mRCC patients treated with TKIs. The biological mechanisms suggesting and explaining this correlation are not well known and different speculative theories have been considered in order to investigate the clinical link between hypothyroidism occurrence and the prolonged therapy with TKIs in solid tumors. Furthermore, the management of this unexplained side effect is very important to maximize the efficacy of therapy in mRCC patients because there is a clear and consistent relationship between drug dose and efficacy of treatment. Certainly, other studies are needed to clarify whether a better outcome is associated with hypothyroidism induced to TKIs in patients with mRCC.

AB - The most recent World Health Organization classification of renal neoplasms encompassed nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical outcomes and show different responses to therapy. Overall, the incidence of kidney cancer has increased worldwide in the last years. Although the most common type of kidney cancer is localized renal cell carcinoma (RCC), with a 5-year survival rate of 85%, about one third of patients present advanced or metastatic disease at diagnosis, with a 5-year survival rate of only 10%. Multi-targeted receptor tyrosine kinase inhibitors (TKIs, sunitinib and sorafenib), the anti-VEGF MAB bevacizumab in association with interferon-a, and the mTOR inhibitors are now approved for the treatment of mRCC. Recently, the novel agents pazopanib and axitinib have also demonstrated efficacy in mRCC patients. Several recent retrospective and prospective trials have suggested that some of their adverse events, such as hypertension, hypothyroidism, and hand foot syndrome (HFS) may act as potential biomarkers of response and efficacy of treatment. In this review, we analyzed the studies that have suggested a relationship between hypothyroidism onset and a better outcome of mRCC patients treated with TKIs. The biological mechanisms suggesting and explaining this correlation are not well known and different speculative theories have been considered in order to investigate the clinical link between hypothyroidism occurrence and the prolonged therapy with TKIs in solid tumors. Furthermore, the management of this unexplained side effect is very important to maximize the efficacy of therapy in mRCC patients because there is a clear and consistent relationship between drug dose and efficacy of treatment. Certainly, other studies are needed to clarify whether a better outcome is associated with hypothyroidism induced to TKIs in patients with mRCC.

KW - Carcinoma

KW - Hypothyroidism

KW - Metastatic renal cell

KW - Tyrosine kinase inhibitors

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84886424099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886424099&partnerID=8YFLogxK

U2 - 10.1530/ERC-13-0201

DO - 10.1530/ERC-13-0201

M3 - Article

VL - 20

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 5

ER -